Home > Products > Novel inhibitors
Cat. No. Product name CAS No.
DCC3762 Nsc-311068

Novel selective inhibitor of TET1 transcription and 5-hydroxymethylcytosine (5hmC) modification, effectively inhibiting cell viability in AML with high expression of TET1

73768-68-0
DCC3763 Nsc-33353

Potent inhibitor of the AcrAB-TolC efflux pump in Escherichia coli, potentiating the antibacterial activities of novobiocin and erythromycin upon binding to the membrane fusion protein AcrA

DCC3764 Nsc-339579

Novel potent Mycobacterium tuberculosis DHFR inhibitor

65795-53-1
DCC3765 Nsc339614 Potassium Salt

Selective potentiator at GluN1/GluN2C and GluN1/GluN2D receptors

1135037-53-4
DCC3766 Nsc-347518

DT-diaphorase inhibitor

87626-58-2
DCC3767 Nsc-4231

Novel Rho-Kinase-II Inhibitor with Vasodilatory Activity

5397-55-7
DCC3768 nsc48693 Dihydrochloride

Potent apoptosis inducer in pancreatic cancer cells

1356084-90-6
DCC3769 Nsc52101

Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein

DCC3770 Nsc-55158

Novel antagonist of the Grb7 SH2 domain; Antitumor Agent

5507-11-9
DCC3771 Nsc56452

Novel specific inhibitor of EGF receptor autophosphorylation and cell proliferation in HeLa cells by disrupting allosteric activation of EGF-stimulated dimer

DCC3772 Nsc-57148

Novel antagonist of the Grb7 SH2 domain; Antitumor Agent

4315-44-0
DCC3773 Nsc-57774

Novel potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines

524-11-8
DCC3774 Nsc57971

Novel non-peptide disruptor of IKKß/NEMO complex

6632-11-7
DCC3775 Nsc-60339

Novel efflux pump inhibitor (EPI)

70-09-7
DCC3776 Nsc61610

Novel activator of lanthionine synthetase C-like 2 (LANCL2), down-modulating pulmonary inflammation through the downregulation of TNF-α and MCP-1 and reduction in the infiltration of neutrophils, accelerating recovery and inducing IL-10-mediated regulator

500538-94-3
DCC3777 Nsc-627757

Novel DNA repair inhibitor

DCC3778 Nsc636795

Novel inhibitor of ABCG2 transporter function

66528-28-7
DCC3779 Nsc-657186

Novel selective non-zinc-binding MMP-2 inhibitor

1772-39-0
DCC3780 Nsc65847

Novel dual inhibitor of viral and Streptococcus pneumoniae neuraminidase

6949-15-1
DCC3781 Nsc66098

Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein

3259-43-6
DCC3782 Nsc663627

IκBα phosphorylation inhibitor

51837-75-3
DCC3783 Nsc-670224

Toxitant of Saccharomyces_cerevisiae>Saccharomyces cerevisiae

1374648-47-1
DCC3784 Nsc-672121

Potent CDC25A>Cdc25A inhibitor; Vitamine K3 analogue

59147-84-1
DCC3785 Nsc-674205

Potent and selective nociceptin opioid receptor (NOP) agonist

13130-47-7
DCC3786 Nsc676914a

Novel NF-κB inhibitor

DCC3787 nsc-681152

Novel inhibitor of the Skp2-Cks1 protein-protein interaction and p27(Kip1) ubiquitination in vitro

241128-06-3
DCC3788 Nsc-689857

Novel inhibitor of the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro

241127-79-7
DCC3789 Nsc704342

Novel Inhibitor of HCV NS3/4A Proteinase

DCC3790 Nsc705841

Novel selective serotonin reuptake inhibitor (SSRI), exhibiting higher binding affinities in comparison with the paroxetine

DCC3791 Nsc724526

Novel Inhibitor of HCV NS3/4A Proteinase

DCC3792 Nsc724527

Novel Inhibitor of HCV NS3/4A Proteinase

DCC3793 Nsc-73306

Cytotoxic MDR-selective ligand

79560-74-0
DCC3794 Nsc-741909

Novel anticancer agent, suppressing the growth of several cell lines derived from lung, colon, breast, ovarian, and kidney cancers

92407-91-5
DCC3795 Nsc745885

Novel down-regulator of EZH2, inducing G2/M cell-cycle arrest of cancer cells and degradating p53 via proteasome-dependent and -independent pathways

4219-52-7
DCC3796 nsc746364

Telomerase inhibitor, stabilizing G-quadruplex and suppressing cell growth of A549 human lung cancer cells through activation of the ATR/Chk1-dependent pathway

1190593-30-6
DCC3797 nsc746365 Maleate

Telomerase inhibitor, anticancer agent

209176-53-4
DCC3798 Nsc747854

Novel inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1)

1329520-12-8
DCC3799 Nsc750212

Novel inhibitor of lipid metabolism, disrupting tubulin polymerization,suppressing monoglycerol metabolism depleting lipids and inhibiting the growth of both lymphoma and RCC both in vitro and in vivo

DCC3800 Nsc-77053

The first reported BoNT/E small molecule inhibitor

77308-57-7
DCC3801 Nsc-79887

Novel inhibitor of nucleoside hydrolase (NH)

19056-78-1
DCC3802 Nsc-80141

Selective inhibitor of HsEg5

97027-56-0
DCC3803 Nsc-84096

Potent inhibitor of endopeptidase activity of botulinum neurotoxin type A light chain (rBoNT/A-LC)

908813-78-5
DCC3804 Nsc-8891

Tyrosyl-DNA phosphodiesterase (Tdp1) inhibitor

21170-34-3
DCC3805 Nsc-9037

First-in-class probe of Rad6 function, inhibiting Rad6 function and Rad6-Rad18 interaction in the PCNA ubiquitination cascade

3569-82-2
DCC3806 nsc-96626

Novel B-Raf(V600E) inhibitor

27430-18-8
DCC3807 Nsi-189 Phosphate

Novel stimulator of neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo.

1270138-41-4
DCC3808 Nsmase2-in-1

Novel inhibitor of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases

DCC3809 Nsp-116

Novel free radical scavenger, against light-induced photoreceptor cell damage

DCC3810 Nti-007

Potent anti-HBV agent, targeting the NTCP-APOA1-HBx-Beclin1-mediated autophagic pathway

DCC3811 Ntrc-739

Novel nonpeptide selective ligand for NTS2

DCC3812 Ntrc-808

Novel nonpeptide potent and selective partial agonist of the Neurotensin receptor type 2 (NTS2)

DCC3813 Ntrd22

Novel Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43

DCC3814 Ntr-responsive Protac 17-1

The first NTR-responsive PROTAC, incorporating the caging group on the Von Hippel-Lindau (VHL) E3 ubiquitin ligase ligand, efficiently degrading the EGFR protein and subsequently exert antitumor efficacy

DCC3815 Ntz-15

Novel potent STAT3 inhibitor, exhibiting much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines

DCC3816 Ntz-24

Novel potent STAT3 inhibitor

69819-42-7
DCC3817 Ntzdpa

Novel potent and selective non-thiazolidinedione partial Peroxisome_proliferator-activated_receptor>PPARγ agonist, acting as an antibiotic effectively against bacterial persisters

118414-59-8
DCC3818 Nu6155

Novel potent CDK2 inhibitor

DCC3819 Nuc013

Novel DNA methytransferase inhibitor, be significantly safer and more effective than decitabine in xenograft models of human leukemia and colon cancer

DCC3820 Nucc-201177

Novel highly potent and selective MEK4 inhibitor

DCC3821 Nucc-474

Novel potent activin antagonist

DCC3822 Nucc-555

First-in-class activin antagonist, specifically binding to ALK4, which opens a completely new approach to inhibiting the activity of TGF-beta receptor superfamily members

1060469-90-0
DCC3823 Nucleocidin

Nucleosidic antibiotic

24751-69-7
DCC3824 Nuod-in-25

Novel inhibitor of Helicobacter pylori , targeting H. pylori's respiratory complex I subunit NuoD

DCC3825 Nurf Inhibitor Bz1

Novel Potent Cell-Active Inhibitor of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition

DCC3826 Nusb-nuse Inhibitor-22

Novel Inhibitor of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity

DCC3827 Nusb-nuse Interaction Inhibitor-1

Novel modulator of the NusB-NusE interaction

125966-81-6
DCC3828 Nutlin-1

p53-MDM2 binding inhibitor; p-Glycoprotein (p-gp) transport substrate; Antitumer agent

548472-58-8
DCC3829 Nutlin-2

Potent and selective p53-MDM2 binding inhibitor

548472-76-0
DCC3830 Nv2899

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

174422-13-0
DCC3831 Nv2907

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

DCC3832 Nv2909

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

DCC3833 Nv2913

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

DCC3834 Nvp Cxcr2 Antagonist 14

Novel potent, orally bioavailable CXCR2 receptor antagonist

DCC3835 Nvp Cxcr2 Antagonist 24

Novel potent, orally bioavailable CXCR2 receptor antagonist

DCC3836 Nvp-abe171

Novel phosphodiesterase 4D (PDE4D) inhibitor

426268-06-6
DCC3837 Nvp-abj688

Novel Inhibitor of the Cysteine Protease Cathepsin K

669003-73-0
DCC3838 Nvp-acq090

Novel potent and selective antagonist of somatostatin receptor subtype SST(3)

362612-47-3
DCC3839 Nvp-aht202

Novel BCR-ABL Kinase Inhibitor

DCC3840 Nvp-bhs345

Novel dual inhibitor of TORC1 and TORC2

DCC3841 Nvp-bvb808

Novel potent Jak2 type 1 inhibitor

1414587-22-6
DCC3842 Nvp-cfc218

Novel potent and selective p53-HDM2 inhibitor

1313363-06-2
DCC3843 Nvp-dpp728

Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor

247016-69-9
DCC3844 Nvp-lbm415

Novel peptide deformylase (PDF) inhibitor; Antibacterial

478913-91-6
DCC3845 Nvp-qab205

Novel Syk inhibitor

325165-07-9
DCC3846 Nvp-saa164

Novel nonpeptide bradykinin B1 receptor antagonist

312722-60-4
DCC3847 Nvp-sra880

The first non-peptide somatostatin sst(1) receptor antagonist

573984-99-3
DCC3848 Nvp-tac544

Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R

761436-62-8
DCC3849 Nvp-vid400

Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase)

174262-10-3
DCC3850 Nvp-xaa228

Novel potent PKCθ inhibitor

DCC3851 Nvs-bet-2

Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo

DCC3852 Nvs-mllt-1

Novel Potent and Selective inhibitor of YEATS proteins

DCC3853 Nvs-pak1-c

Negative control for NVS-PAK1-1 (8778)

2250019-95-3
DCC3854 Nvs-sm2

Potent, orally active, small-molecule enhancer of SMN2 splicing, binding to and stabilizing the U1 snRNP:5′ss RNA complex

1562333-92-9
DCC3855 Nvx-108

Exceptional oxygen transporter, increasing brain tissue oxygen tension (PbtO2) when administered soon after traumatic brain injury (TBI)

678-26-2
DCC3856 Nw-1772

Highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor

911290-35-2
DCC3857 Nxd30001

Novel potent Hsp90 inhibitor, inducing tumor regression in a genetically engineered mouse model of glioblastoma multiforme

1223580-83-3
DCC3858 nxn-188

Selective nNOS inhibitor and a5-HT1B/1D receptor agonist

6634-56-6
DCC3859 Nybomycin

Anti-microbial agent against Mycobacterium smegmatis and Mycobacterium bovis BCG, binding to DNA and inducing a unique morphological change to mycobacterial bacilli leading the bacterial cell death

26326-47-6
DCC3860 Ny-eso-1

Cancer-testis antigen (CTA) with re-expression in numerous cancer types, eliciting spontaneous humoral and cellular immune responses, restricting expression pattern, being a good candidate target for cancer immunotherapy

344422-47-5
DCC3861 Nystatin-3

Novel water-soluble nystatin derivative, being fully water-soluble (up to 1 g/mL) with the same potency of Nystatin but with 13.5 times lower toxicity

DCC3862 O-1302

Potent CB1 receptor antagonist

336615-76-0
DCC3863 O-1663

Novel inhibitor of advanced stages of breast cancer, targeting multiple cannabinoid anti-tumour pathways

468083-84-3
DCC3864 o-1918

Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly.

536697-79-7
DCC3865 Oa-adp-hpd

Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor

DCC3866 Oat-1441

Novel Selective and Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase (hAMCase)

2088453-79-4
DCC3867 O-bn-thaz Fumarate

Potent agonist of the human 5-HT2A and 5-HT2C receptors

1420459-43-3
DCC3868 Obtusaquinone

Natural potent antineoplastic agent with promising in vivo activity in glioblastoma and breast cancer through the activation of oxidative stress

21105-15-7
DCC3869 Obtusilactone A

Inhibitor of mitochondrial Lon protease and activator of DNA damage checkpoints

56522-15-7
DCC3870 Obtusilactone B Featured

Specific inhibitor of vaccinia-related kinase 1 (VRK1)-mediated phosphorylation of barrier-to-autointegration factor (BAF)

58940-66-2
DCC3871 O-carbamate 66

Novel potent antileishmanial and antitrypanosomal agent, offering a more optimal balance of increased solubility, suitable metabolic stability, excellent oral bioavailability (100%), and strong in vivo efficacy in a visceral leishmaniasis mouse model (97%

DCC3872 Ocean Blue Se

Blue fluorescent labeling reagent

215868-33-0
DCC3873 Octamoxin

Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI)

4684-87-1
DCC3874 Octimibate

Potent non-prostanoid inhibitor of platelet aggregation, acting via the prostacyclin receptor

89838-96-0
DCC3875 Octreotideacetate GMP grade Featured

Agonist of sst2, sst3 and sst5 somatostatin receptors

83150-76-9
DCC3876 Ofh243

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist

DCC3877 Ofh244

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist

DCC3878 Ofh3911

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist

DCC3879 Ofh3912

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist

DCC3880 Og488-bapta-1-am

Cell-permeable, fluorescent Ca2+ indicator

244167-57-5
DCC3881 Oga-in-5i

Novel potent O-GlcNAcase (OGA) inhibitor (IC 50 : 46 nM), increasing the level of O-GlcNAcylated protein in cells and displaying suitable pharmacokinetic properties and brain permeability

DCC3882 Ohinitib

Novel HSF1 inhibitor for target-based cancer therapy

DCC3883 Oh-nplh2

Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo

DCC3884 Oicr766a

Novel Bax activator, having greatest effect enhancing the pro-apoptotic activity of Bax with EC50 values of ∼0.1 μM and ∼0.9 μM, respectively, inducing cell death by a Bax/Bak-dependent mechanism

DCC3885 Ojak-989

Novel orally bioavailable potent JAK-1 inhibitor

1315485-91-6
DCC3886 Okadaic Acid

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

78111-17-8
DCC3887 Okadaic Acid Potassium Salt

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

209266-79-5
DCC3888 Okadaic Acid Sodium Salt

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

209266-80-8
DCC3889 Olanzapine Pamoate

Dopamine antagonist as an atypical antipsychotic

221373-18-8
DCC3890 Olanzapine/samidorphan

Combination of the atypical antipsychotic olanzapine and opioid receptor antagonist samidorphan for treatment of adults with schizophrenia or bipolar I disorder

132539-06-1
DCC3891 Oleanonic Acid

Natural inhibitor of the phosphorylation of protein kinase C ζ (PKCζ) at Thr410 site, reducing the activation of NF-κB using gain- and loss-of-function approaches in PE-treated cardiomyocytes, ameliorating pressure overload-induced cardiac hypertrophy

17990-42-0
DCC3892 Oleracein E

Potent antioxidant and neuroprotectant for treatment of Parkinson's disease, reducing reactive oxygen species (ROS) levels, inhibiting extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, reducing rotenone-induced up-regulation of the proapopt

1021950-79-7
DCC3893 Olfr895-agonist-10

Novel specific agonist of odorant receptor 895 (Olfr895)

2098493-67-3
DCC3894 Olmutinib Hydrochloride

Novel Bruton's tyrosine kinase inhibitor, suppressing B cell and monocyte activation and ameliorates arthritis in a mouse model

1842366-97-5
DCC3895 Olprinone

Phosphodiesterase III inhibitor, augmenting cerebral blood flow by a direct vasodilator effect on cerebral arteries

106730-54-5
DCC3896 Omdm-188

Novel potent DAGL inhibitor, inhibiting collagen-, but not arachidonic acid-induced aggregation and TxA2 synthesis

1072902-75-0
DCC3897 On012380

Non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I

592543-24-3
DCC3898 Oncrasin-72

Potent analogue of oncrasin-1 with antitumor activity mediated by JNK activation and STAT3 inhibition

92407-90-4
DCC3899 Ono12380

Novel non-ATP-competitive inhibitor of BCR-ABL, overriding imatinib resistance

936915-58-1
DCC3900 Ono-2910

Novel enhancer of Schwann cell differentiation for treatment of peripheral nerve disorder

2410177-35-2
DCC3901 Ono-3307

Protease inhibitor

76472-28-1
DCC3902 Ono-4007

Lipid A analog, inducing Th1-type immune response in tumor eradication and restoring nitric oxide production by peritoneal macrophages

152646-95-2
DCC3903 Ono-4310321

Potent, orally available dual CysLT1 and CysLT2 receptor antagonist

908131-71-5
DCC3904 Ono-ae1-259

Highly selective agonist of prostaglandin E2 receptor (EP2)

365497-70-7
DCC3905 Ono-ae1-259 Lysine

Novel selective EP2 receptor agonist, inducing relaxation of smooth muscle

433232-03-2
DCC3906 Ono-ae1-329

Novel agonist of the prostaglandin PGE2 receptor EP4

253350-43-5
DCC3907 Ono-ae2-227

EP(4)-selective antagonist

357605-73-3
DCC3908 Ono-ae-248

Novel selective EP3 receptor agonist

211230-67-0
DCC3909 Ono-ae3-237

Potent, selective, and orally active prostaglandin D2 receptor antagonist

DCC3910 Oopz-23-l(nle)aq

Novel potent inhibitor of protein-protein interactions

1610618-54-6
DCC3911 Opc-13213

Metabolite of Cilostazol

87153-04-6
DCC3912 Opc-14117

Antioxidant and free radical scavenger, attenuating edema formation, and subsequent tissue damage following cortical contusion

103233-65-4
DCC3913 Ophiobolin A

Inhibitor of calmodulin action in calcium regulation

4611-05-6
DCC3914 Optoglunam4.1

Novel negative allosteric modulator (NAM) of mGlu4, being isomerized with blue-light/dark cycles with fast relaxation

DCC3915 Orc-13661 Hydrochloride

Novel Potent, Well Tolerated, and Orally Active Protective Agent against Aminoglycoside-Induced Hearing Loss

1589571-77-6
DCC3916 Orcein

Collagen immunostain

1400-62-0
DCC3917 Orex-1019

Novel mixed κ/μ receptor antagonist. having therapeutic potential for the treatment of depression and other stress-induced conditions

DCC3918 Org-27759

Negative allosteric modulator at the CB1 receptor

868273-09-0
DCC3919 Org-29647

CB1 allosteric modulator

868273-12-5
DCC3920 Org48762-0

Selective p38alpha and p38beta kinase inhibitor

755753-89-0
DCC3921 Oritavancin

Lipoglycopeptide Antibacterial, acting as a inhibitor of Cytochrome P450 2C19/2C9, and a inducer of Cytochrome P450 3A4/2D6

171099-57-3
DCC3922 orm-10103

Novel sodium/calcium exchanger (NCX) inhibitor

488847-28-5
DCC3923 Orn0829

Novel potent dual orexin 1/2 receptor (OX1/2R) antagonist for the treatment of insomnia

2265899-49-6
DCC3924 Oroidin Hydrochloride

Inhibitor of an enzyme responsible for the multidrug resistance phenotype in the yeast Saccharomyces cerevisiae.

202391-65-9
DCC3925 Orp-101

Peripheral weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist, preventing from being absorbed and entering the central nervous system

1820753-68-1
DCC3926 Ortataxel

Second-generation taxane derivative with potential antineoplastic activity, binding to and stabilizing tubulin molecules, inhibiting cell division and cellular proliferation

186348-23-2
DCC3927 Oseltamivir Hydrochloride

Inhibitor of the influenza neuramidase enzyme, blocking neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles

204255-09-4
DCC3928 Osi-296

Novel potent, orally efficacious, dual inhibitor of cMET and RON kinases

1175296-94-2
DCC3929 Osi-461

Novel cGMP phosphodiesterase (cGMP-PDE) inhibitor

279238-68-5
DCC3930 Osl-95ii

Inhibitor of the glycan-processing enzyme endoplasmic-reticular glucosidase

946603-07-2
DCC3931 Osteoclast Differentiation Inhibitor T63

Novel inhibitor of osteoclast differentiation through regulating MAPKs and Akt signaling pathways

DCC3932 Osteoprotegerin

Soluble secreted member of the tumor necrosis factor receptor superfamily, inhibiting osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, leading to excess accumulation of bone and cartilage

19220-35-0
DCC3933 Osteosarcoma-in-d14

Novel Inhibitor of Migration and Invasion of Osteosarcoma Cells Mediated by p53, Regulating EMT-Related Genes

1372198-10-1
DCC3934 Osteosarcoma-in-d15

Novel Inhibitor of Migration and Invasion of Osteosarcoma Cells Mediated by p53, Regulating EMT-Related Genes

DCC3935 Osu-53

Novel AMPK activator, inhibiting mTOR signaling and autophagy stimulation, activating mutations in RAS or BRAF

1290069-19-0
DCC3936 Ota-5781

Novel potent inhibitor of the natural function of FDX1, promoting a unique form of copper-dependent cell death

DCC3937 Ouabain

Natural inhibitor of the Na+/K+-ATPase sodium-potassium ion pump

630-60-4
DCC3938 oup-186

High affinity and human/rat species-selective histamine H3 receptor antagonist

1480830-24-7
DCC3939 Ova257-264 Peptide

Ovalbumin fragment peptide as a class I (Kb)-restricted peptide epitope, triggering T cell activation in immunology studies

138831-86-4
DCC3940 Ova323-339 Peptide

Ovalbumin fragment peptide for study class II MHC-peptide binding and T-cell activation, binding to I-A(d) MHC class II protein, encompassing an allergenic and antigenic epitope of the ovalbumin protein

92915-79-2
DCC3941 Ovatodiolide

Narural broad anticancer agent, upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway

3484-37-5
DCC3942 Ov-potentiator-28

First-in-class small molecule potentiator of cancer virotherapy, significantly enhancing virus replication-associated luciferase expression specifically in the tumor

1976033-03-0
DCC3943 Ox02983

Novel anthelmintic agent, immobilising whipworm and reducing the ability of embryonated T. muris eggs to establish infection in the mouse host in vivo

DCC3944 Ox03699

Novel anthelmintic agent

DCC3945 Ox1r Antagonist 56

Brain penetrant, selective and high affinity OX1R antagonist

DCC3946 Ox2r-in-f7.3

Novel selective Ligand for the Orexin 2 Receptor (OX2R)

1259173-43-7
DCC3947 Oxa-06 Dihydrochloride

Potent inhibitor of PANC-1 cell migration and MYPT1 phosphorylation

944955-32-2
DCC3948 Oxaz-1

Novel dual inhibitor of the p53 interaction with MDM2 and MDMX

DCC3949 Oxeglitazar

PPARalpha/gamma agonist

280585-34-4
DCC3950 Oxendolone

Novel potent inhibitor of GVIA iPLA2 with little or no inhibition against GIVA cPLA2 (XI(50) = 0.0073 and >0.91, respectively)

33765-68-3
DCC3951 Oxfbd03

Novel inhibitor of the bromodomain and extra terminal domain (BET) bromodomain family member BRD4(1)

1429129-71-4
DCC3952 Oxiperomide Featured

Dual dopamine D2 and muscarinic M1 receptor ligand with putative antipsychotic and pro-cognitive potential

5322-53-2
DCC3953 Oxocarbazate

Novel inhibitor of human cathepsin L

DCC3954 Oxs000675

Novel inducer of differentiation in all six AML cell lines

DCC3955 Oxt-328

Novel sulindac derivative; anti-inflammatory and anti-cancer agent

1118973-90-2
DCC3956 Oxyfedrine Hydrochloride

Vasodilator and β-adrenoreceptor agonist

16777-42-7
DCC3957 Oxyl Surfen

Antagonist of cell-surface heparan sulfate and heparin-protein interactions, reducing tau hyperphosphorylation and mitigating or delaying neuronal defects in tauopathies, including Alzheimer's disease

DCC3958 Oxymetholone

Synthetic hormone with anabolic and androgenic properties

434-07-1
DCC3959 Oxymorphindole

δ-Opioid receptor agonist

111469-88-6
DCC3960 P18in005 Hydrochloride

Novel p18(INK4C) inhibitor

7403-44-3
DCC3961 P18smi-21

Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein

20535-76-6
<Prev1...152153154155156...172Next>